Aug 13, 2025 8:00am EDT Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results
Aug 11, 2025 9:15am EDT Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13
Aug 04, 2025 7:30am EDT Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset
Aug 01, 2025 7:45am EDT Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company’s Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression
Jul 09, 2025 7:50am EDT Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium
Jul 07, 2025 7:45am EDT Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model
Jun 30, 2025 7:45am EDT Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
Jun 26, 2025 8:00am EDT Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing
Jun 05, 2025 9:00am EDT Artelo’s Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study
